List of Orilissa drug patents
Orilissa is owned by Abbvie Inc.
Orilissa contains Elagolix Sodium.
Orilissa has a total of 6 drug patents out of which 0 drug patents have expired.
Orilissa was authorised for market use on 23 July, 2018.
Orilissa is available in tablet;oral dosage forms.
Orilissa can be used as management of moderate to severe pain associated with endometriosis using 150mg elagolix while co-administering rifampin, management of moderate to severe pain associated with endometriosis, use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women to reduce dysmenorrhea and non-menstrual pelvic pain; use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women having dyspareunia associated with endometriosis, management of moderate to severe pain associated with endometriosis using 150 mg elagolix while co-administering ketoconazole.
Drug patent challenges can be filed against Orilissa from July, 2022.
The generics of Orilissa are possible to be released after 01 September, 2036.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7419983 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
Jul, 2024
(1 year, 4 months from now) | |
| US7056927 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(1 year, 7 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7176211 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jul, 2024
(1 year, 4 months from now) | |
| US11344551 | ABBVIE INC | Methods of treating heavy menstrual bleeding |
Mar, 2034
(11 years from now) | |
| US10537572 | ABBVIE INC | Methods of administering elagolix |
Sep, 2036
(13 years from now) | |
| US10682351 | ABBVIE INC | Methods of administering elagolix |
Sep, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 23, 2023 |
Drugs and Companies using ELAGOLIX SODIUM ingredient
NCE-1 date: July, 2022
Market Authorisation Date: 23 July, 2018
Treatment: Management of moderate to severe pain associated with endometriosis; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women to reduce dysmenorrhea and non-menstrual pelvic pain; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women having dyspareunia associated with endometriosis; Management of moderate to severe pain associated with endometriosis using 150mg elagolix while co-administering rifampin; Management of moderate to severe pain associated with endometriosis using 150 mg elagolix while co-administering ketoconazole
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic